Altamonte Springs, FL, October 29, 2021 — Cord for Life®, a full-service cord blood bank with over 25 years of experience, today announced plans to conduct a clinical trial to treat lower back pain arising from the Sacroiliac Joint (SIJ) using a biological therapeutic derived from umbilical cord blood. [Read more…]
Vitti Labs Announces FDA Approval of IND Application for Phase II Trial of Combination MSC and Exosome Treatment of COVID-19
LIBERTY, Mo., Oct. 26, 2021 — Vitti Labs (www.vittilabs.com), an AATB Accredited Tissue Bank focused on Life Science Research, Development and Manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination of Umbilical Cord Mesenchymal Stem Cell and Umbilical Cord Mesenchymal Stem Cell Exosomes for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with the Novel Corona Virus (COVID-19). This marks the very first time the FDA has approved an IND that uses both of these components together and so first of its kind therapy. [Read more…]
Curi Bio and NEXEL Form Celogics, a Joint Venture to Develop iPSC-Derived Products
Celogics, based in Seattle, will offer high-quality iPSC-derived cell products for drug discovery and safety testing.
OCTOBER 26, 2021, SEATTLE and SEOUL – Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA. [Read more…]
Therapeutic Solutions Utilizes MSC Exosomes to Suppress Inflammatory Pathologies
-
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
-
Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies
ELK CITY, Idaho, Oct. 4, 2021 — Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced laboratory data demonstrating that exosomes produced by JadiCells™, the Company’s Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps. [Read more…]
Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with “Top 100 Innovation CEO” Award
September 21, 2021, Palo Alto, California – Koji Tanabe, Founder and CEO of I Peace, Inc., has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021”. [Read more…]
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 97
- Next Page »